Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
Trial details
- Registry ID
- NCT05322473
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis SuppurativaNCT05322473 | MoonLake Immunotherapeutics AG | Phase 2 | Completed | 2023-05-09Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |